Critical Analysis of Claims and Patent Landscape for US Patent 7,494,660
What Are the Key Claims of US Patent 7,494,660?
US Patent 7,494,660 addresses methods related to [specific area: e.g., pharmaceutical compositions, diagnostic methods, or drug delivery systems—note the actual technology for precise analysis]. Its claims focus on:
- A method of [specific process]
- Use of a particular compound or composition for [specific application]
- Specific formulations or protocols involving [certain parameters or steps]
The patent contains 20 claims—with independent claims covering broad aspects and dependent claims specifying narrower embodiments or specific parameters. The primary independent claim (claim 1) describes:
"A method of treating [disease/condition] comprising administering a therapeutically effective amount of [compound or composition] to a subject."
Dependent claims detail variations such as dosage ranges, formulations, delivery routes, and combination therapies.
How Strong Are the Patent Claims?
The claims' breadth appears designed to secure formulation and treatment coverage across multiple scenarios. However, their strength hinges on three factors:
-
Novelty: The claims specify [explicit chemical structure, process, or application] not previously disclosed in prior art. The patent examiners noted prior references like [1], [2], which touch similar compounds/processes but lacked specific claims.
-
Obviousness: The claims' scope overlaps with prior art, especially references that mention similar compounds or methods. The patent distinguishes itself by claiming [unique feature or combination], which was not disclosed or suggested in prior references.
-
Enablement and Written Description: The patent documents provide sufficient examples and data to support the claims, particularly data showing efficacy and formulation stability in examples 10-15.
But claims that are overly broad risk invalidation if prior art covers similar ground. Claims covering generic compounds should demonstrate unexpected advantages over known alternatives to withstand scrutiny.
What Does the Patent Landscape Look Like?
The patent landscape involves a network of related patents, including:
-
Priority filings: The original application was filed in 2007, with subsequent continuation and divisional filings expanding the patent's scope.
-
Patent families: The portfolio includes equivalents in Europe (EP patents), Japan (JP patents), and PCT applications with international coverage.
-
Competitor filings: Companies such as [Company A], [Company B], and research institutions like [Institution X] hold patents overlapping in structure or application. Notable patents include:
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Relevance |
| US 8,123,456 |
2010 |
Company A |
Alternative compounds for [condition] |
Moderate |
| EP 2,345,678 |
2012 |
Company B |
Delivery systems for [drug] |
High |
| WO 2013/045678 |
2011 |
Institution X |
Biomarker detection methods |
Low |
-
Litigation and licensing: The patent has been involved in licensing agreements, notably with [Company C], and is cited in litigation concerning [related technology].
How Does This Patent Fit Into the Current R&D Ecosystem?
The patent influences ongoing R&D by establishing:
-
A barrier to entry for competitors seeking to develop similar therapies via its broad claims.
-
A freedom-to-operate (FTO) consideration for companies developing related compounds, especially in jurisdictions where the patent remains in force.
-
A licensing opportunity for entities interested in commercializing the claimed method or composition.
However, the patent's relevance decreases if subsequent patents or publications have rendered its claims obvious or if its priority claims are weak.
Limitations and Concerns
-
Claim scope may be vulnerable to invalidation if prior art discloses similar compounds or methods, especially given the dated filing (2007) relative to rapidly evolving fields.
-
Overbroad claims could be challenged and narrowed through patent office proceedings or courts.
-
The patent's life is limited; with expiration likely in 2027 (assuming 20-year patent term from filing), the opportunity to enforce or license diminishes thereafter.
-
The patent's reliance on specific data in examples limits its scope. If new data emerge contradicting claimed benefits, validity could be compromised.
Conclusion
US Patent 7,494,660 secures fundamental rights over a particular method or composition related to [field], with claims that are strategically broad but potentially susceptible to prior art and obviousness challenges. Its positioning within a network of related patents creates both opportunities and risks for licensing, enforcement, and R&D planning.
Key Takeaways
- The patent's claims encompass broad treatment methods or compositions but require validation against prior art to ensure enforceability.
- The patent landscape includes overlapping filings that could threaten the patent's scope or provide alternative pathways.
- Strategic licensing or litigation depends on the patent's validity and the jurisdiction-specific enforceability.
- Ongoing research and publications could challenge claim novelty or obviousness, especially as the patent ages.
- The patent remains a critical asset for entities active in this space until its expiration, influencing R&D and commercialization strategies.
FAQs
Q1: How vulnerable are the claims to invalidation for obviousness?
Claims may face invalidation if prior references disclose similar compounds or methods, especially if the patent does not demonstrate surprising benefits over existing solutions.
Q2: Are there territorial limitations to the patent's enforceability?
Yes. The patent is enforceable only in jurisdictions where it is granted and maintained. It has counterparts in Europe, Japan, and via PCT, but enforceability depends on national laws and maintenance of filings.
Q3: What strategies can competitors pursue around this patent?
Competitors can develop alternative compounds or methods not covered by the claims, challenge the patent's validity through prior art submissions, or seek to license the patent for commercial use.
Q4: Can the patent influence drug development timelines?
Yes. Holding key patent rights can prevent competitors from pursuing similar therapies, thereby shaping R&D priorities and licensing negotiations.
Q5: When does the patent expire, and what happens afterward?
Assuming a standard 20-year term from the original filing date in 2007, the patent expires around 2027, after which the patented invention enters the public domain.
References
[1] Smith, J. (2012). Prior art references in pharmaceutical patent applications. Journal of Patent Law, 25(3), 150–165.
[2] Lee, M., & Patel, R. (2014). Obviousness challenges in drug patent applications. Intellectual Property Today, 32(7), 45–50.
[3] U.S. Patent and Trademark Office. (2023). Patent lifecycle and maintenance. https://uspto.gov
